STOCK TITAN
  1. Home
  2. Sec-filings
  3. COLL
  4. [8-K] COLLEGIUM PHARMACEUTICAL, INC Reports Material Event

Collegium (NASDAQ: COLL) shareholders back board, pay and auditor at 2026 meeting

Filing Impact
(Moderate)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Collegium Pharmaceutical, Inc. reported results of its 2026 Annual Meeting of Shareholders. A total of 32,406,969 common shares were entitled to vote as of March 31, 2026, and 29,210,926 shares were represented in person or by proxy.

Shareholders elected eight directors, including Rita Balice-Gordon and Garen Bohlin, to serve until the 2027 Annual Meeting. On an advisory basis, shareholders approved the compensation of the company’s named executive officers. Shareholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

Positive

  • None.

Negative

  • None.
Item 5.07 Submission of Matters to a Vote of Security Holders Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Shares entitled to vote 32,406,969 shares Common stock entitled to vote as of March 31, 2026
Shares represented at meeting 29,210,926 shares Shares present in person or by proxy at 2026 Annual Meeting
Say-on-pay votes for 26,313,792 votes Advisory approval of named executive officer compensation
Say-on-pay votes against 1,100,723 votes Advisory compensation proposal opposition
Auditor ratification votes for 28,953,181 votes Ratification of Deloitte & Touche LLP for FY ending December 31, 2026
Director example – votes for 27,379,677 votes Votes for director nominee Nancy Lurker
broker non-votes financial
"Abstentions | | | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
on an advisory basis financial
"Approval of, on an advisory basis, the compensation of the Company’s named executive officers"
named executive officers financial
"the compensation of the Company’s named executive officers"
Named executive officers are the senior company leaders whose names, roles and compensation are singled out in required regulatory filings; this typically includes the chief executive, chief financial officer and the next highest‑paid senior officers. Investors treat this list like a team roster — it shows who makes key decisions, how they are paid and whether incentives align with shareholder interests, so changes or pay patterns can signal governance quality, risk or strategic shifts.
Annual Meeting of Shareholders financial
"held its 2026 Annual Meeting of Shareholders"
A yearly gathering where a company’s owners (shareholders) vote on key items like electing the board, approving executive pay, and ratifying auditors, and receive updates on performance and strategy. Think of it as an annual town hall for owners: it matters to investors because outcomes and disclosures can affect leadership, corporate direction, dividend and governance policies, and therefore the company’s risk and potential return.
Understanding 8-K Material Events →
false 0001267565 0001267565 2026-05-14 2026-05-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): May 14, 2026

 

COLLEGIUM PHARMACEUTICAL, INC.

(Exact Name of Registrant as Specified in its Charter)

 

Virginia   001-37372   03-0416362
(State or Other Jurisdiction
of Incorporation or Organization)		   (Commission File Number)   (IRS Employer Identification
No.)

 

100 Technology Center Drive
Suite 300
Stoughton, MA 02072
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code: (781) 713-3699

  

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common stock, par value $0.001 per share COLL The NASDAQ Global Select Market

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

 

Item 5.07Submission of Matters to a Vote of Security Holders.

 

On May 14, 2026, Collegium Pharmaceutical, Inc. (the “Company”) held its 2026 Annual Meeting of Shareholders (the “Annual Meeting”). A total of 32,406,969 shares of common stock of the Company were entitled to vote as of March 31, 2026, the record date for the Annual Meeting, of which 29,210,926 were present in person or by proxy at the Annual Meeting.  The following is a summary of the final voting results for each matter presented to shareholders.

 

PROPOSAL 1:

 

Election of eight Directors to hold office until the 2027 Annual Meeting of Shareholders.

 

Nominee  For   Against   Abstentions   Broker Non-Votes 
Rita Balice-Gordon   25,890,238    1,343,456    186,467    1,790,765 
Garen Bohlin   27,093,924    243,649    82,588    1,790,765 
Michael Donovan   27,383,194    35,519    1,448    1,790,765 
John Freund, M.D.   26,907,371    510,601    2,189    1,790,765 
Vikram Karnani   27,243,959    173,863    2,339    1,790,765 
Nancy Lurker   27,379,677    39,738    746    1,790,765 
Carlos Paya, M.D., Ph.D.   26,695,542    710,809    13,810    1,790,765 
Gino Santini   26,824,258    593,714    2,189    1,790,765 

 

Each of Rita Balice-Gordon, Garen Bohlin, Michael Donovan, John Freund, Vikram Karnani, Nancy Lurker, Carlos Paya and Gino Santini was elected by the Company’s shareholders as Directors to hold office until the 2027 Annual Meeting of Shareholders.

 

PROPOSAL 2:

 

Approval of, on an advisory basis, the compensation of the Company’s named executive officers.

 

For   Against   Abstentions   Broker Non-Votes 
 26,313,792    1,100,723    5,646    1,790,765 

 

On an advisory basis, the Company’s shareholders approved the compensation of the Company’s named executive officers.

 

PROPOSAL 3:

 

Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.

 

For   Against   Abstentions   Broker Non-Votes 
 28,953,181    252,815    4,930    0 

 

Proposal 3 was approved by the Company’s shareholders.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Dated: May 15, 2026 Collegium Pharmaceutical, Inc.
     
  By: /s/ Colleen Tupper
    Name: Colleen Tupper
    Title: Executive Vice President and Chief Financial Officer

 

 

 

Source: View Original Filing on SEC EDGAR

FAQ

What did Collegium Pharmaceutical (COLL) shareholders vote on at the 2026 Annual Meeting?

Shareholders voted on three items: electing eight directors until the 2027 Annual Meeting, approving named executive officer compensation on an advisory basis, and ratifying Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.

How many Collegium Pharmaceutical (COLL) shares were represented at the 2026 Annual Meeting?

A total of 32,406,969 Collegium Pharmaceutical common shares were entitled to vote as of March 31, 2026. Of these, 29,210,926 shares were present in person or by proxy, providing the voting base for all proposals considered at the 2026 Annual Meeting.

Were Collegium Pharmaceutical’s executive compensation practices approved at the 2026 meeting?

Yes. On an advisory basis, shareholders approved the compensation of Collegium Pharmaceutical’s named executive officers, with 26,313,792 votes for, 1,100,723 against, 5,646 abstentions, and 1,790,765 broker non-votes recorded on the say-on-pay proposal at the 2026 Annual Meeting.

Who was elected to Collegium Pharmaceutical’s board at the 2026 Annual Meeting?

Eight nominees were elected as directors to serve until the 2027 Annual Meeting: Rita Balice-Gordon, Garen Bohlin, Michael Donovan, John Freund, Vikram Karnani, Nancy Lurker, Carlos Paya, and Gino Santini, each receiving more votes for than against, with additional broker non-votes reported.

Which auditor did Collegium Pharmaceutical (COLL) shareholders ratify for 2026?

Shareholders ratified Deloitte & Touche LLP as Collegium Pharmaceutical’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,953,181 votes for, 252,815 against, 4,930 abstentions, and no broker non-votes recorded on the auditor ratification proposal.

Filing Exhibits & Attachments

3 documents

Other Documents